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Background: Disruption of the sarcolemma-associated dystrophin-glycoprotein complex underlies multiple forms
of muscular dystrophy, including Duchenne muscular dystrophy and sarcoglycanopathies. A hallmark of these
disorders is muscle weakness. In a murine model of Duchenne muscular dystrophy, mdx mice, cysteine-nitrosylation
of the calcium release channel/ryanodine receptor type 1 (RyR1) on the skeletal muscle sarcoplasmic reticulum
causes depletion of the stabilizing subunit calstabin1 (FKBP12) from the RyR1 macromolecular complex. This results
in a sarcoplasmic reticular calcium leak via defective RyR1 channels. This pathological intracellular calcium leak
contributes to reduced calcium release and decreased muscle force production. It is unknown whether RyR1
dysfunction occurs also in other muscular dystrophies.
Methods: To test this we used a murine model of Limb-Girdle muscular dystrophy, deficient in β-sarcoglycan
(Sgcb−/−).
Results: Skeletal muscle RyR1 from Sgcb−/− deficient mice were oxidized, nitrosylated, and depleted of the
stabilizing subunit calstabin1, which was associated with increased open probability of the RyR1 channels.
Sgcb−/− deficient mice exhibited decreased muscle specific force and calcium transients, and displayed reduced
exercise capacity. Treating Sgcb−/− mice with the RyR stabilizing compound S107 improved muscle specific force,
calcium transients, and exercise capacity. We have previously reported similar findings in mdx mice, a murine model
of Duchenne muscular dystrophy.
Conclusions: Our data suggest that leaky RyR1 channels may underlie multiple forms of muscular dystrophy linked
to mutations in genes encoding components of the dystrophin-glycoprotein complex. A common underlying
abnormality in calcium handling indicates that pharmacological targeting of dysfunctional RyR1 could be a novel
therapeutic approach to improve muscle function in Limb-Girdle and Duchenne muscular dystrophies.
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Muscular dystrophies (MD) comprise a group of in-
herited disorders affecting striated muscles that are
characterized by progressive weakness and muscle de-
generation. The dystrophin-glycoprotein complex (DGC)
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proteins (α-, β-, δ-, and γ-sarcoglycan), which maintain
fiber integrity and protect from contraction-induced
muscle damage [1,2]. Mutation-induced disruption of
sarcoglycan proteins leads to limb-girdle muscular dys-
trophy (LGMD) [3-5]. A null mutation in one of the
sarcoglycans results in loss of the whole sarcoglycan
complex but not of dystrophin [4,6]. However muta-
tions in dystrophin, which cause the most common
form of muscular dystrophy, Duchenne muscular dys-
trophy (DMD), also lead to loss of the sarcoglycanstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tral upstream event in muscular dystrophies. Disrup-
tion of the DGC is associated with oxidative stress,
activation of Ca2+-dependent neutral proteases (cal-
pains) [8], mitochondrial Ca2+ overload, and apoptosis
[9,10]. Moreover, pathological Ca2+ signaling has been
attributed to MDs [11-17].
Skeletal muscle contraction is regulated by a process
known as excitation-contraction (E-C) coupling. A crit-
ical feature of this process is the release of Ca2+ from
the sarcoplasmic reticulum (SR) via the intracellular Ca2+
release channel/ryanodine receptor type 1 (RyR1). To ini-
tiate E-C coupling, depolarization of the cell membrane
activates L-type calcium channels (Cav1.1) on the trans-
verse tubule, which then activates RyR1 through the dir-
ect interaction between the two ion channels, causing
release of Ca2+ from the SR into the cytoplasm. The in-
crease in Ca2+ enables the actin-myosin cross-bridge for-
mation and sarcomere shortening that results in muscle
contraction [18].
RyR1 is a macromolecular complex with associated
regulatory proteins including kinases, phosphatases,
and the peptidyl-propyl-cis-trans-isomerase FK506
binding protein 12 (FKBP12, also known as calstabin1).
Calstabin1 binds to RyR1 and stabilizes the closed state
of the channel, thereby preventing a potentially patho-
logical Ca2+ leakage from the SR [19]. RyR1 has multi-
ple cysteine residues that can be S-nitrosylated and
S-glutathionylated at physiological pH [20]. These modi-
fications can destabilize the closed state of the RyR1,
which results in a pathological cytoplasmic Ca2+ ‘leak’
[21]. The RyR1 is, moreover, susceptible to oxidation-
dependent modifications and we have recently shown
that SR Ca2+ ‘leak’ contributes to age-dependent muscle
weakness [22]. Furthermore, inhibition of this intracellu-
lar Ca2+ leak with a novel drug that stabilizes the RyR
(S107) [22,23] reduces SR Ca2+ leak and improves muscle
function in aged mice [22] and in the mdx mouse model
of DMD [23].
In the present study we show that β-sarcoglycan-
deficient mice (Sgcb−/− mice; an established murine
model of LGMD) [3], display RyR1 phosphorylation, S-
nitrosylation and oxidation, Ca2+ leak through RyR1, re-
duced tetanic Ca2+, and specific force in isolated fast
twitch EDL muscles. Treatment with S107 reduced the
Ca2+ leak, increased muscle Ca2+ release, force pro-
duction, and improved voluntary exercise capacity in
Sgcb−/− mice. Disruption of the DGC leads to a
common molecular pathophysiological mechanism in
both DMD and LGMD that involves maladaptations
of the RyR1 and Ca2+ leak. Furthermore, this disease
phenotype is likely to respond to therapy with a Ca2+
leak-reducing compounds and thus presents new pharma-
ceutical strategies in treating muscular dystrophies.Methods
Animals
Homozygous β-sarcoglycan deficient mice (Strain: B6.129-
Sgcbtm1Kcam/1 J; in this article referred to as Sgcb−/−) were
obtained from The Jackson Laboratory (Bar Harbor, ME,
USA) [3,24]. The Sgcb−/− mice were backcrossed for
several generations into C57Bl/6 background and aged-
matched C57Bl/6 mice were used as controls. All ex-
periments with animals were approved by Columbia
University’s Institutional Animal Care and Use Committee.
Voluntary exercise and S107 treatment
At the beginning of each experiment mice were trans-
ferred to individual cages equipped with running wheels
and exercise was recorded using a data acquisition sys-
tem (Respironics). The mice were acclimated to the run-
ning wheels for 7 to 9 days and were randomized into
two treatment groups. The first group received S107
(25 mg/100 mL) in the drinking water and the second
group received water only. S107 (S107-HCl, FW 245.77)
was synthesized as previously described [25-27]. The
structure and purity of S107 were confirmed by NMR,
MS, and elemental analysis [25]. The specificity of S107
was assessed against a panel of >250 channels, receptors,
phosphatases, and kinases [25]. Mice drank approxi-
mately 9 mL/day (water bottle and body weight were
recorded to monitor consumption) for a daily dose of
S107 of approximately 1.5 mg. There was no difference
in daily water consumption between the treatment
groups (mean ± SEM: control, 9.9 ± 0.6 mL, S107, 9.3 ±
0.9 mL; n= 5, P=NS). Mice were sacrificed using CO2
followed by cervical dislocation and muscles were har-
vested for functional and biochemical analyses. Investi-
gators performing all aspects of the studies were blinded
to the treatment groups.
Muscle function
Extensor digitorum longus (EDL) muscles were dissected
from hind limbs. Stainless steel hooks were tied to the
tendons of the muscles using nylon sutures and the
muscles were mounted between a force transducer (Har-
vard Apparatus) and an adjustable hook. The muscles
were immersed in a stimulation chamber containing
O2/CO2 (95/5%) bubbled Tyrode solution (in mM: NaCl
121, KCl 5.0, CaCl2 1.8,3 MgCl2 0.5, NaH2PO4 0.4,
NaHCO3 24, EDTA 0.1, glucose 5.5). Muscles were sti-
mulated to contract using an electrical field between two
platinum electrodes (Aurora Scientific). At the start of
each experiment the muscle length (L0) was adjusted to
yield the maximum force. The force-frequency relation-
ships were determined by triggering contraction using
incremental stimulation frequencies (EDL: 0.5 ms pulses
at 2 to 150 Hz for 350 ms at supra-threshold voltage).
The muscles were allowed to rest between every force-
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force measurement, the L0 and weight of the muscles
were measured and the muscles were snap frozen in li-
quid N2. To quantify the specific force, the absolute
force was normalized to the muscle cross-sectional area,
calculated as the muscle weight divided by the length
using a muscle density constant of 1.056 kg*m-3 [28].
Muscle fatigue protocol
After force-frequency measurements, the EDL muscle
was fatigued. The fatigue protocol for the EDL muscle
consisted of 50 tetanic contractions (70 Hz, 350 ms dur-
ation) given at 2-s intervals.
RyR1 immunoprecipitation and immunoblotting
EDLs were isotonically lysed in 0.5 mL of a buffer con-
taining 50 mM Tris–HCl (pH 7.4), 150 mM NaCl,
20 mM NaF, 1.0 mM Na3VO4, and protease inhibitors.
An anti-RyR antibody (4 μg 5029 Ab) was used to im-
munoprecipitate RyR1 from 250 μg of tissue homogen-
ate. The samples were incubated with the antibody in
0.5 mL of a modified RIPA buffer (50 mM Tris–HCl pH
7.4, 0.9% NaCl, 5.0 mM NaF, 1.0 mM Na3VO4, 1% Tri-
ton-X100, and protease inhibitors) for 1 h at 4°C. The
immune complexes were incubated with protein A
Sepharose beads (Sigma, St Louis, MO, USA) at 4°C for
1 h and the beads were washed three times with buffer.
Proteins were separated on SDS-PAGE gels (6% for
RyR1, 15% for calstabin1) and transferred onto nitrocel-
lulose membranes for 1 h at 200 mA (SemiDry transfer
blot, Bio-Rad). After incubation with blocking solution
(LICOR Biosciences, Lincoln, NE, USA) to prevent non-
specific antibody binding, immunoblots were developed
with anti-RyR (Affinity Bioreagents, Bolder, CO, USA;
1:2,000), and anti-Cys-NO antibody (Sigma, St Louis, MO,
USA; 1:2,000), or an anti-calstabin antibody (1:2,500).
To determine channel oxidation the carbonyl groups on
the protein side chains were derivatized to 2,4- dinitro-
phenylhydrazone (DNP-hydrazone) by reaction with 2,4
dinitrophenylhydrazine (DNPH). The DNP signal on
RyR1 was detected by immunoblotting with an anti-DNP
antibody. All immunoblots were developed and quanti-
fied using the Odyssey Infrared Imaging System (LICOR
Biosystems, Lincoln, NE, USA) and infrared-labeled sec-
ondary antibodies.
SR vesicle preparation
About 100 mg of isolated mouse EDL muscle was
homogenized using a tissue mizer (Fisher Scientific) at
the highest speed for 1 min with two volumes of:
20 mM Tris-maleate (pH 7.4), 1 mM EDTA, and prote-
ase inhibitors (Roche). Homogenate was centrifuged at
4,000 g for 15 min at 4°C and the following supernatant
was centrifuged at 40,000 g for 30 min at 4°C. The finalpellet, containing the SR fractions, was resuspended and
aliquoted using the following solution: 250 mM sucrose,
10 mM MOPS (pH 7.4), 1 mM EDTA, and protease
inhibitors. Samples were frozen in liquid nitrogen and
stored at −80°C.
Single-channel recordings
SR vesicles containing RyR1 were fused to planar lipid
bilayers formed by painting a lipid mixture of phosphati-
dylethanolamine and phosphatidylcholine (Avanti Polar
Lipids) in a 3:1 ratio in decane; across a 200-μm hole in
polysulfonate cups (Warner Instruments) separating two
chambers. The trans chamber (1.0 mL), representing the
intra-SR (luminal) compartment, was connected to the
head stage input of a bilayer voltage clamp amplifier.
The cis chamber (1.0 mL), representing the cytoplasmic
compartment, was held at virtual ground. Solutions used
were the following: (in mM): 1 mM EGTA, 250/125 mM
Hepes/Tris, 50 mM KCl, 0.54 mM CaCl2, pH 7.35 as cis
solution, and 53 mM Ca(OH)2, 50 mM KCl, 250 mM
Hepes, pH 7.35 as trans solution. The concentration of
free Ca2+ in the cis chamber was calculated with Win-
MaxC program (version 2.50; www.stanford.edu/~cpat-
ton/maxc.html). SR vesicles were added to the cis side
and fusion with the lipid bilayer was induced by making
the cis side hyperosmotic by the addition of 400 to
500 mM KCl. After the appearance of potassium and
chloride channels, the cis side was perfused with the cis
solution. Single-channel currents were recorded at 0 mV
by using a Bilayer Clamp BC-525 C (Warner Instru-
ments), filtered at 1 kHz using a Low-Pass Bessel Filter 8
Pole (Warner Instruments), and digitized at 4 kHz. To
confirm RyR identity, 5 μM of ryanodine and/or 20 μM
of ruthenium red were added at the end of each ex-
periment. All experiments were performed at room
temperature (23°C). Po was determined over 2 min of
continuous recording using the method of 50% threshold
analysis [29]. The recordings were analyzed by using
Clampfit 10.1 (Molecular Devices) and Sigma Plot soft-
ware (ver. 10.0, Systat Software), and Prism (ver.5.0,
GraphPad).
Ca2+ imaging in FDB muscle fibers
Single FDB fibers were obtained by enzymatic dissoci-
ation as previously described [30]. FDB muscles from
both hind limbs were incubated for approximately 2 h at
37°C in approximately 4 mL Dulbecco’s Modified Eagles
Medium (DMEM) containing 0.3% collagenase 1 (Sigma)
and 10% fetal bovine serum. The muscles were trans-
ferred to a culture dish containing fresh DMEM (ap-
proximately 4 mL) and gently triturated using a 1,000
μL pipette until the muscles were dissociated. The cell
suspension was stored in an incubator at 37°C/5% CO2
until the start of the experiment. FDB fibers were loaded
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Invitrogen/Molecular probes) for 15 min in RT. The
cells were allowed to attach to a laminin-coated glass
cover slip that formed the bottom of a perfusion cham-
ber. The cells were then superfused with tyrode solution
(in mM: NaCl 121, KCl 5.0, CaCl2 1.8, MgCl2 0.5,
NaH2PO4 0.4, NaHCO3 24, EDTA 0.1, glucose 5.5;
bubbled with O2/CO2 (95/5%)). The fibers were trig-
gered to tetanic contraction using electrical field stimu-
lation (pulses of 0.5 ms at supra-threshold voltage, at
70 Hz for 350 ms) and Fluo-4 fluorescence was moni-
tored using confocal microscopy (Zeiss LSM 5 Live, 40x
oil immersion lens, excitation wavelength was 488 nm
and the emitted fluorescence was recorded between
495 nm and 525 nm) in linescan mode. Only cells that
were firmly attached to the glass bottom dish through-
out the tetanic stimulation were included in the analysis.
After subtraction of background fluorescence, the change
in fluorescent signal during the tetanus (peak–resting
(ΔF)) was divided by the resting signal (ΔF/F0). All ex-
periments were performed at RT (approximately 20°C).
The investigators were blinded to the genotype and
treatment of subjects.
Histology
The EDL samples were fixed with formalin, embedded
in paraffin wax, and sliced at 5 μm thickness. The sec-
tions were deparaffinized, stained with hematoxylin and
eosin (H&E staining, Sigma-Aldrich Co., St Louis, MO,
USA) and observed using light microscopy. The images
were captured using a SPOT RTslider camera (Diagnostic
Instruments Inc., Sterling Heights, MI, USA). For mor-
phological analysis, images were taken randomly from
each section using a computer controlled motorized
stage. Then each image was analyzed by Image-Pro Plus
software (Media Cybernetics, Inc., Bethesda, MD, USA).
The judgment of qualitative parameters was performed
by a clinical pathologist blinded to the mouse genotype.
Degenerated fibers were defined as having weaker eosin
staining, which was furthermore confirmed by weaker
Gomori Trichrome staining (examples weak eosin stain-
ing is indicated by asterisks in Figure 1B). Necrotic fibers
were defined as a swollen/degraded fiber with loss of
eosin stain, with or without inflammatory cell infiltration
(example is indicated by a circle in Figure 1B).
Transmission electron microscopy
EDL muscles were fixed in 2.5% glutaraldehyde in 0.1 M
Sorenson’s buffer (PH 7.2) followed by 1 h of post-
fixation with 1% OsO4 in Sorenson’s buffer. After dehy-
dration the tissue samples were embedded in Lx-112
(Ladd Research Industries) and 60 nm sections were cut
using an ultramicrotome (MT-7000). The sections were
then stained with uranyl acetate and lead citrate andexamined under an electron microscope (JEM-1200
EXII, JEOL) and images were taken using an ORCA-HR
digital camera (Hamamatsu) and recorded with an AMT
Image Capture Engine.Results and discussion
Muscular dystrophy is accompanied by abnormal muscle
morphology, including fiber degeneration and focal ne-
crosis, which are associated with an enhanced regenerative
activity in the muscle [3,31-33]. To confirm the dystrophic
phenotype in the Sgcb−/− mice, we examined histopatho-
logical changes in EDL muscles from β-sarcoglycan-
deficient mice compared to WT (Figure 1A-E). A majority
(approximately 75%) of the muscle fibers from Sgcb−/−
mice displayed centrally localized nuclei as opposed to the
subsarcolemmal nuclei that are normally found in the
healthy WT muscle (Figure 1C). This finding is consistent
with regenerative activity in the muscle and has previously
been reported in β-, and δ-sarcoglycan-deficient muscle
[3,32,33]. Moreover, the Sgcb−/− muscle displayed overt
histopathological changes, with a high prevalence of
degenerated and necrotic fibers and a larger variability
in the muscle fiber size (Figure 1B, D, and E). These
morphological changes are typical for muscular dys-
trophy [3,32,33]. Mitochondrial abnormalities have also
been described in patients [34] and murine models [9,31]
of muscular dystrophy. Accordingly, ultrastructural ana-
lysis of EDL muscles from Sgcb−/− mice revealed many
fibers with abnormal mitochondrial morphology, such as
swelling and loss of cristae structure (Figure 1F, G). How-
ever, the sarcomere ultrastructure appeared normal in
the Sgcb−/− muscle fibers (Figure 1F, G).
A hallmark of muscular dystrophies is limb muscle
weakness [7]. We used extensor digitorum longus (EDL)
muscles from 4- to 6-month-old Sgcb−/− mice and aged-
matched wild-type controls (WT) to examine muscle
force production. Isolated EDL muscles were electrically
stimulated to contract and force production was mea-
sured. EDL muscle from Sgcb−/− mice displayed reduced
absolute force compared to WT (mean tetanic force at
70 Hz stimulation ± SEM: Sgcb−/−, 280 ± 24 mN, vs. WT,
420 ± 30 mN; n= 9 (Sgcb−/−), n= 6 (WT); P <0.01 (t-test)).
When the force was normalized to muscle cross-
sectional area (specific force) the Sgcb−/− EDL muscles
exhibited reduced specific force (mean force at 70 Hz
stimulation ± SEM: Sgcb−/−, 200 ± 20 kNm-1, vs. WT,
440 ± 30 kNm-1; n= 9 (Sgcb−/−), n= 6 (WT); P <0.01
(T-test)), indicating defective force generation that is
independent of muscle size. A pathognomonic sign in
LGMD is the presence of pseudo-hypertrophy. Indeed,
the EDL muscle mass was increased in Sgcb−/− (Sgcb−/−,
18 ± 1 mg, vs. WT, 13 ± 0.4; n= 9 (Sgcb−/−), n= 6 (WT);
P <0.001), as previously published [6,35].
Figure 1 EDL muscles from β-sarcoglycan deficient mice exhibit dystrophic morphology and abnormal mitochondrial morphology. (A,
B) EDL muscle cross-sections from wild-type (WT) and β-sarcoglycan mice stained with hematoxylin and eosin. (C) Percentage of fibers with the
nucleus localized in the center (average ± SEM). (D) Percentages of normal, degenerated (weak eosin staining, examples indicated by asterisk)
and necrotic (loss of eosin stain and swollen fiber, example indicated by a circle) muscle fibers. (E) Fiber size was more variable in Sgcb−/− EDL.
This is indicated by the difference in the frequency distribution of fiber cross-sectional area. The inset in (E) is an expansion of the region
indicated by the dashed rectangle in the main graph. Data were obtained from four mice and> 600 fibers in each group. The scale bar in images
(A) and (B) indicate 250 μm. Representative electron microscopy images of EDL muscle from (F) WT and (G) Sgcb−/− mice. Arrows indicate
normal mitochondria (F) or mitochondria with abnormal morphology, including low cristae density (G). Images from 11 fibers and two mice in
each group were investigated under blinded conditions. The sample is magnified at × 25,000. Scale bar indicates 500 nm.
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muscle specific force were associated with remodeling of
the RyR1 macromolecular complex, RyR1 were immu-
noprecipitated and immunoblotted to assay for post-
translational modifications [23]. Skeletal muscle RyR1
channels from Sgcb−/− mice exhibited significantly in-
creased phosphorylation, oxidation, and nitrosylation
(Figure 2A, B). Moreover, phosphorylation, oxidation,
and nitrosylation cause loss of calstabin1 from the RyR1
complex [22,23,36] and Sgcb−/− muscle RyR1 were
depleted of calstabin1 (Figure 2A, B).
Treatment with the 1,4-benzothiazepine derivative,
S107, inhibits calstabin1 depletion from the RyR1 com-
plex, stabilizes the closed state of the RyR1 channel, and
improves muscle strength in mdx mice as well as in
24-month-old mice with age-related muscle weakness
[22,23]. We therefore examined whether S107 could in-
hibit the loss of muscle function in Sgcb−/− mice by ran-
domizing Sgcb−/−mice to receive drinking water without
(n= 6) or with S107 (25 mg/100 mL, n= 6). The treat-
ment persisted for approximately 4 weeks after whichthe animals were sacrificed and biochemistry and muscle
function were assayed. Immunoprecipitation and im-
munoblotting of RyR1 indicated that there was increased
calstabin1 bound to RyR1 in the S107 treated Sgcb−/−
mice (Figure 2A, B).
Preserved RyR1-calstabin1 interaction is associated
with reduced SR Ca2+ leak, improved Ca2+ release, mus-
cle function, and exercise capacity [18]. To assess the
presence of RyR1-dependent Ca2+ leak, we measured
single channel open probability (Po) of the RyR1 using
SR membranes from fast twitch muscles that were fused
to planar lipid bilayers. Experimental conditions mimick-
ing resting skeletal muscle (90 nM Ca2+ on the cis, ‘cyto-
solic’ side) were used. The Po of RyR1 from the Sgcb−/−
mice was increased (Figure 3A, B, and D), and S107
treatment resulted in a significant reduction in RyR1 Po
(Figure 3C, D). These data are consistent with ‘leaky’
RyR1 [22,23]. To study SR Ca2+ release, we loaded iso-
lated fast twitch flexor digitorum brevis (FDB) muscle
fibers with the fluorescent Ca2+ indicator Fluo-4 AM
and electrically stimulated the fibers to produce tetanic
Figure 2 RyR1 in β-sarcoglycan deficient muscle is cysteine-
nitrosylated, oxidized, and depleted of calstabin1. (A)
Representative immunoblot of immunoprecipitated RyR1 from wild-
type (WT) and β-sarcoglycan deficient (Sgcb−/−) EDL muscles.
Antibodies against RyR1-S2844 phosphorylation (P*RyR1), cysteine-
nitrosylated (Cys NO) proteins, calstabin1, and the protein oxidation
marker 2,4- dinitrophenylhydrazone (DNP) was used. The muscle
from a mouse treated with S107 is marked (+). (B) Bar graph
showing average band intensities normalized to RyR1 expression
(mean± SEM, n= 3 for all groups).
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cytes from Sgcb−/− mice (Figure 3E, F). The S107-treated
Sgcb−/− displayed increased Ca2+ transients compared to
untreated Sgcb−/− (mean tetanic F/F0 ± SEM: WT, 17 ±
0.8 (n= 6); Sgcb−/−, 10 ± 0.6 (n= 20); Sgcb−/− S107, 13 ±
0.8 (n= 26); cells were taken from three mice per group,
P < 0.05 (ANOVA); Figure 3E, F).
We next measured force production in isolated EDL
muscles. There was a significant increase in EDL specific
force in the S107-treated Sgcb−/− mice (mean tetanic
forces at 70 Hz stimulation ± SEM: Sgcb−/− S107, 320 ±
20 kNm-1, Sgcb−/− control 200±20 kNm-1; n=9 (Sgcb−/−),
n= 6 (Sgcb−/− S107), P <0.001 (t-test); Figure 4A). A
marked feature of skeletal muscle is its susceptibility to
fatigue and recovery. EDL muscles from S107-treated
and untreated Sgcb−/− mice were repeatedly stimulated
to tetanic contractions. The degree of force reduction
during fatigue as well as the recovery was similar in both
groups (Figure 4B, C). However, the EDL from S107-
treated mice exhibited increased force production prior
to the fatigue protocol. Therefore the EDL from S107-
treated mice exhibited higher force production through-
out the fatigue protocol and would likely sustain higher
levels of work in vivo [30,37]. To determine whether the
improvements in muscle function corresponded to in-
creased exercise capacity, voluntary running performance
was recorded in S107-treated and untreated Sgcb−/−
mice. S107-treated Sgcb−/− mice ran longer and faster
(mean daily running distance after 5 weeks ± SEM: WT,
6.2 ± 0.4 km, Sgcb−/− S107, 3.8 ± 0.3 km, Sgcb−/− 1.5 ±
0.4 km, n= 8–5, P <0.05 (ANOVA); Figure 4D, E).In the present study we show that RyR1 in dystrophic
muscle are oxidized, cysteine-nitrosylated, phosphory-
lated, and depleted of calstabin1, resulting in ‘leaky’
channels, decreased fast twitch muscle force, and im-
paired exercise capacity. Furthermore, we show that
treating β-sarcoglycan-deficient mice with the RyR sta-
bilizing drug, S107, preserves RyR1-calstabin1 binding,
increases SR Ca2+ release, fast twitch muscle force, and
improves voluntary exercise capacity.
Mutations in components of the DGC or in DGC-
associated proteins cause several different muscular dystro-
phies, including DMD, the congenital muscular dystrophies,
and LGMD [4]. Previous studies have shown that SR Ca2+
release is reduced in muscle from the dystrophic mdx
mouse model [15-17]. Moreover, it was recently reported
that mdx muscle display increased Ca2+ spark frequency
[23,38]. This is consistent with increased RyR1-mediated
Ca2+ leak. In the present study, leaky RyR1 was seen in
Sgcb−/− muscle as evidenced by increased RyR1 open
probability (Figure 3A-D). Interestingly, it was recently
shown that overexpression of the SR Ca2+ ATPase (SERCA)
in dystrophic mice could rescue the pathological phenotype
in the muscle by effectively pumping excess Ca2+ back into
the SR [33]. Taken together, these data indicate that intra-
cellular Ca2+ leak is a prominent, but reversible, patho-
logical mechanism in muscular dystrophies. It is possible
that cessation of Ca2+ leak would lead to reduction of di-
verse pathogenic signals in muscular dystrophy, including
those affecting gene expression, protease activity, or redox
homeostasis. For instance, the activity of Ca2+-dependent
proteases such as the calpains are increased in muscular
dystrophy and have been attributed a role in the breakdown
of myofillament proteins [33,39]. Inhibition of this process
has been suggested as a therapeutic strategy in myopathies
[8]. In addition to improving SR Ca2+ release, S107 treat-
ment could potentially lead to increased muscle force by
preventing Ca2+-dependent remodeling of the myofilaments.
Electron micrographs from Sgcb−/− EDL muscles dis-
played abnormal mitochondrial morphology (Figure 1F,
G). Mitochondrial defects have previously been described
in both patients [34] and murine models [9,31] of muscu-
lar dystrophy. Ultrastructural analysis of diaphragm
muscle from α-sarcoglycan-null mice revealed disrupted
and swollen mitochondria [31]. Furthermore, Ca2+ over-
load leading to mitochondrial dysfunction has been linked
to activation of cell death pathways in δ-sarcoglycan de-
ficient mice [9], and we have recently reported that
mitochondrial ROS dependent oxidation of RyR1 creates
a vicious cycle of SR Ca2+ leak via RyR1 causing mito-
chondrial Ca2+ overload and exacerbating mitochondrial
ROS production in muscle aging [22].
Cardiomyopathy is a common symptom of muscle
dystrophy [40,41] and improved cardiac function is seen
following S107 treatment of heart failure (post-myocardial
Figure 3 β-sarcoglycan deficient muscle displays RyR1 dysfunction and defective SR Ca2+ release that is restored by S107 treatment.
(A-C) Representative RyR1 single channel current traces in samples from WT (A), Sgcb−/− (B), and Sgcb−/− S107 (C) treated mice. Channel
activity was measured at 90 nmol/L (nM) free cytosolic [Ca2+]. Channel openings are shown as upward deflections; the closed (c -) state of the
channel is indicated by horizontal bars in the beginning of each tracing. For each group, channel activity is illustrated by four different traces,
each of 5 s length as indicated by dimension bars. The single channel open probability (Po), To (mean open time) and Tc (mean closed time)
were calculated from a 2 min recording under 90 nmol/L free cytosolic [Ca2+] are shown above the upper trace. (D) Bar graph summarizing RyR1
single channel Po under 90 nmol/L free cytosolic [Ca2+] from WT (n= 4; white bar), Sgcb−/− (n= 3; black bar), and Sgcb−/−+ S107 (n= 4; red bar)
samples. Data presented as mean± S.E.M; * P <0.05; ** P <0.01 (ANOVA). (E) Representative tetanic Ca2+ transients (normalized Fluo-4
fluorescence) in FDB muscle fibers from wild-type (WT), β-sarcoglycan-deficient control (Sgcb−/−), and S107-treated β-sarcoglycan-deficient
(Sgcb−/− S107) mice. (F) Average Ca2+ transient amplitudes (±SEM, n= 6 (WT) n =20 (Sgcb−/−), n= 26 (Sgcb−/− S107) cells from three mice in
each group, * P <0.05, ** P <0.01 (ANOVA)).
Figure 4 S107 treatment increases muscle force and exercise capacity in β-sarcoglycan deficient mice. (A) Force-frequency curves of EDL
muscle from WT control, β-sarcoglycan-deficient (Sgcb−/−), and S107-treated Sgcb−/− (Sgcb−/− S107) mice. (B) Fatigue stimulation (50 tetani;
each tetanic stimulation had a duration of 350 ms and was produced by stimulating the muscle with 0.5 ms pulses at 70 Hz frequency) on the
same muscles as (A). (C) Relative decline in force production during fatigue in (B). EDL force measurements are presented as mean± SEM, n=6–9.
(D, E) Exercise capacity in Sgcb−/− mice is improved by S107. Daily voluntary running distance (D) and average running speed (E). Pooled data
are presented as mean± SEM, n= 8–5, * P <0.05 (ANOVA).
Andersson et al. Skeletal Muscle 2012, 2:9 Page 7 of 9
http://www.skeletalmusclejournal.com/content/2/1/9
Andersson et al. Skeletal Muscle 2012, 2:9 Page 8 of 9
http://www.skeletalmusclejournal.com/content/2/1/9infarction) and in mdx mice [41,42]. Sgcb−/− mice that
were treated with S107 displayed improved exercise cap-
acity, measured as voluntary running distance and speed.
Exercise capacity is a compound measure that involves
the function of several organ systems. Therefore, it is
possible that improved cardiac function in Sgcb−/− mice
following S107 treatment could contribute to the im-
proved running capacity, this is unlikely however since
the cardiac function was normal by echocardiography in
these mice (data not shown). Moreover, muscle function
is a central determinant of exercise capacity [37] and the
reduced tetanic Ca2+ and impaired muscle specific force
that is seen in Sgcb−/− were improved by fixing the skel-
etal muscle SR Ca2+ leak with S107 and these features
were associated with improved voluntary exercise.
Conclusions
We show here that remodeling of the RyR1 contributes
to skeletal muscle weakness and reduced exercise cap-
acity in Sgcb−/− mice, a model of LGMD. This is con-
sistent with results from a previous study of the mdx
mouse, in which RyR1 were S-nitrosylated, and displayed
SR Ca2+ leak through the RyR1 [23]. The pathophysio-
logical similarities between the two types of muscular
dystrophy, which both result from disruption of the DGC,
suggest that RyR1-mediated SR Ca2+ leak is a common
mechanism for DGC-related muscular dystrophy. Fur-
thermore, this mechanism can be targeted for treatment
with the orally available 1,4-benzothiazepine derivative
S107. Thus, the present findings suggest the possibility
of a novel therapeutic strategy in muscular dystrophy.
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